Market Overview

GRAIL Announces Appointment of Hal Barron and Hans Bishop to its Board of Directors


GRAIL, Inc., a healthcare company whose mission is to detect cancer
early, when it can be cured, today announced the appointment of Hal
Barron, MD, and Hans Bishop to its Board of Directors.

"We are delighted to welcome Hal and Hans to our Board. They are both
known for being exceptional leaders who are committed to making an
impact for people suffering from disease," said Jennifer Cook, Chief
Executive Officer of GRAIL. "We look forward to benefiting from their
significant scientific and corporate experience as we continue on our
path to develop early detection products and alleviate the global cancer

Hal Barron is globally recognized for his clinical and scientific
leadership. He is the Chief Scientific Officer and President of R&D at
GlaxoSmithKline (GSK). Prior to his role at GSK, Dr. Barron was Calico's
President of R&D. Previously, he was Executive Vice President, Head of
Global Product Development, and Chief Medical Officer of Roche
Pharmaceuticals. Prior to this, he was Senior Vice President and Chief
Medical Officer of Genentech. Dr. Barron is also Associate Adjunct
Professor of Epidemiology and Biostatistics at the University of
California, San Francisco. Dr. Barron holds a bachelor's degree in
physics from Washington University in St. Louis and a medical degree
from Yale University.

Hans Bishop has more than 30 years of experience in the biotechnology
industry. Mr. Bishop currently serves on the Board of Directors of
Celgene and Agilent Technologies. Mr. Bishop founded Juno Therapeutics
in 2013 and served as its President and Chief Executive Officer until
the company was acquired by Celgene in March 2018. Prior to this, he
served as an Executive in Residence at Warburg Pincus. Earlier, he was
Executive Vice President and Chief Operating Officer for Dendreon, Inc.
He also previously served as President of Specialty Medicine at Bayer
Healthcare, Senior Vice President of Global Commercial Operations at
Chiron Corporation, and Vice President and General Manager of European
Biopharmaceuticals. Mr. Bishop holds a bachelor's degree in chemistry
from Brunel University in London.


GRAIL is a healthcare company whose mission is to detect cancer early,
when it can be cured. GRAIL is using the power of high-intensity
sequencing, population-scale clinical studies, and state-of-the-art
computer science and data science to enhance the scientific
understanding of cancer biology, and to develop and commercialize
pioneering products for the early detection of cancer. The company is
located in Menlo Park, California and Hong Kong. It is supported by
leading global investors and pharmaceutical, technology, and healthcare
companies. For more information, please visit

View Comments and Join the Discussion!